Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of thymocyte migration. [GOC:mah]
Positive regulation of thymocyte migration is a crucial step in the development and maturation of T cells within the thymus. This process involves a complex interplay of molecular signals and cellular interactions that guide the movement of immature thymocytes from the cortex to the medulla of the thymus. Here's a detailed breakdown:
**1. Initial Entry and Commitment:**
- Immature thymocytes, derived from hematopoietic stem cells in the bone marrow, enter the thymus through the corticomedullary junction.
- They express both CD4 and CD8 coreceptors, indicating their undifferentiated state.
**2. Cortical Development:**
- In the cortex, thymocytes undergo a selection process, interacting with thymic epithelial cells (TECs) and dendritic cells (DCs).
- These interactions involve the presentation of self-antigens on MHC molecules.
- Successful interactions lead to positive selection, ensuring that thymocytes recognize self-MHC molecules, a prerequisite for immune system function.
**3. Medullary Migration:**
- Positively selected thymocytes migrate from the cortex to the medulla.
- This migration is guided by chemokines, small signaling molecules that attract specific cells.
- Key chemokines involved in this process include CCL21, CCL25, and CXCL12.
**4. Medullary Selection:**
- In the medulla, thymocytes interact with medullary TECs and DCs.
- These cells present a broader range of self-antigens, including those expressed in peripheral tissues.
- This interaction allows for negative selection, eliminating thymocytes that react strongly to self-antigens, preventing autoimmunity.
**5. Exit and Maturation:**
- Thymocytes that successfully navigate positive and negative selection mature into single-positive T cells, expressing either CD4 or CD8.
- They acquire their final effector functions, including the ability to recognize and respond to specific foreign antigens.
- Mature T cells exit the thymus through the corticomedullary junction and enter the bloodstream, ready to patrol the body for pathogens.
**Molecular Players:**
- **Chemokines:** CCL21, CCL25, CXCL12, CXCL13
- **Adhesion molecules:** Integrins, ICAMs, VCAMs
- **Signaling pathways:** S1P signaling, CCR7 signaling, Sphingosine-1-phosphate receptor (S1PR) signaling
- **Transcription factors:** NF-κB, FoxP3, GATA3
**Key Factors Influencing Migration:**
- **Thymic microenvironment:** The specific organization and cellular composition of the thymus, including the presence of TECs, DCs, and stromal cells, significantly influence thymocyte migration.
- **Stage of thymocyte development:** Different stages of thymocyte maturation are characterized by distinct expression profiles of receptors and signaling molecules, affecting their migration behavior.
- **Immune status:** During infections or inflammation, thymocyte migration can be modulated by changes in chemokine expression and other signaling pathways.
Overall, positive regulation of thymocyte migration is a dynamic and multifaceted process that ensures the proper selection and differentiation of T cells within the thymus, guaranteeing a robust and self-tolerant immune system.'
"
Protein | Definition | Taxonomy |
---|---|---|
C-C chemokine receptor type 2 | A C-C chemokine receptor type 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P41597] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
amiodarone | amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias. Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. | 1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound | cardiovascular drug |
disulfiram | organic disulfide; organosulfur acaricide | angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor | |
fasudil | fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia. fasudil: intracellular calcium antagonist; structure in first source | isoquinolines; N-sulfonyldiazepane | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent |
nifedipine | Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. | C-nitro compound; dihydropyridine; methyl ester | calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent |
dibenzothiazyl disulfide | dibenzothiazol-2-yl disulfide : An organic disulfide resulting from the formal oxidative coupling of the thiol groups of two molecules of 1,3-benzothiazole-2-thiol. It is used as an accelerator in the rubber industry. dibenzothiazyl disulfide: vulcanizing accelerant | benzothiazoles; organic disulfide | allergen |
1-naphthylisothiocyanate | 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage. | isothiocyanate | insecticide |
plerixafor | plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2 | azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound | anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant |
rosiglitazone | aminopyridine; thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug | |
fasudil hydrochloride | fasudil hydrochloride : A hydrochloride obtained by reaction of fasudil with one equivalent of hydrochloric acid. | hydrochloride | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; neuroprotective agent; nootropic agent; vasodilator agent |
tak 779 | |||
bay 11-7085 | BAY11-7085 : A sulfone that is benzene substituted by [(E)-2-cyanoethenyl]sulfonyl and tert-butyl groups at position 1 and 4, respectively. It is an irreversible inhibitor of IkappaB-alpha phosphorylation in cells (IC50 = 10 muM) and prevents the activation of NF-kappaB. | benzenes; nitrile; sulfone | anti-inflammatory agent; antibacterial agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; ferroptosis inducer; NF-kappaB inhibitor |
ucb 35625 | UCB 35625: J-113863 is the (trans)-isomer; structure in first source | ||
rs 504393 | RS 504393: structure in first source | 1,3-oxazoles | |
incb3344 | INCB3344: potent and selective small molecule CCR2 chemokine receptor antagonist | ||
amd 070 | mavorixafor: a derivative of AMD3100; a CXCR4 blocker | aminoquinoline | |
cenicriviroc | cenicriviroc : A member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). cenicriviroc: an inhibitor of HIV-1 | aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide | anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist |
incb 3284 | INCB 3284: a CCR2 receptor antagonist | ||
azd8309 | AZD8309: CXCR2 inhibitor | ||
n-(carbamoylmethyl)-3-trifluoromethyl benzamido-4-chlorobenzyl 3-aminopyrrolidine |